FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281755343> ?p ?o ?g. }

• W4281755343 endingPage "8519" @default.
• W4281755343 startingPage "8519" @default.
• W4281755343 abstract "8519 Background: The role of adjuvant therapy in patients with completely resected stage IB non-small-cell lung cancer (NSCLC) remains to be determined. Icotinib is standard-of-care therapy for patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutation. This phase II study investigated whether adjuvant therapy with icotinib improves the clinical outcome compared with observation in patients with EGFR mutation-positive resected stage IB NSCLC. Methods: This phase II, open-label, randomized study (GASTO1003, CORIN) was conducted at Sun Yat-sen University Cancer Center. From May 2013 to December 2020, patients with completely resected, EGFR mutation-positive, stage IB (7th TNM staging for NSCLC) NSCLC without adjuvant chemotherapy according to physician and patient choices were enrolled. The patients were assigned in a 1:1 ratio to receive adjuvant therapy with icotinib (125mg, three times daily) for 12 months or to undergo observation. Therapy continued until disease progression or intolerable toxicity. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and toxicity. Survival endpoints were assessed in the intention-to-treat population. Results: Three patients withdrew consent and were excluded. A total of 128 patients were enrolled and randomized, with 63 patients in the icotinib group and 65 patients in the observation group. Baseline characteristics were well balanced between the groups. The median duration of follow-up was 34.9 months. A total of 13 recurrence events occurred, including 2 in the icotinib arm and 11 in the observation arm. DFS was significantly longer among those in the icotinib arm than among those in the observation arm (hazard ratio: 0.20, 95% confidence interval, 0.04-0.89; P = 0.018). The 3-year DFS for the icotinib and observation arms were 95.3% and 86.7%, respectively. The OS data were immature with 3 deaths in the observation arm. The safety profile was consistent with the known safety profile of icotinib. Icotinib was well tolerated with no unexpected adverse events. No treatment-related death occurred. Conclusions: Adjuvant icotinib shows prolonged DFS and acceptable toxicity in patients with completely resected EGFR-mutated stage IB NSCLC. Ajuvant icotinib provides a treatment option for these patients. Clinical trial information: NCT02264210." @default.
• W4281755343 created "2022-06-13" @default.
• W4281755343 creator A5003421579 @default.
• W4281755343 creator A5024351287 @default.
• W4281755343 creator A5025904134 @default.
• W4281755343 creator A5034080288 @default.
• W4281755343 creator A5036954594 @default.
• W4281755343 creator A5037403084 @default.
• W4281755343 creator A5044450333 @default.
• W4281755343 creator A5045065281 @default.
• W4281755343 creator A5048411184 @default.
• W4281755343 creator A5077294466 @default.
• W4281755343 date "2022-06-01" @default.
• W4281755343 modified "2023-10-18" @default.
• W4281755343 title "Adjuvant icotinib versus observation in patients with completely resected, EGFR-mutated, stage IB non–small cell lung cancer (GASTO1003, CORIN): A randomized phase II trial." @default.
• W4281755343 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.8519" @default.
• W4281755343 hasPublicationYear "2022" @default.
• W4281755343 type Work @default.
• W4281755343 citedByCount "0" @default.
• W4281755343 crossrefType "journal-article" @default.
• W4281755343 hasAuthorship W4281755343A5003421579 @default.
• W4281755343 hasAuthorship W4281755343A5024351287 @default.
• W4281755343 hasAuthorship W4281755343A5025904134 @default.
• W4281755343 hasAuthorship W4281755343A5034080288 @default.
• W4281755343 hasAuthorship W4281755343A5036954594 @default.
• W4281755343 hasAuthorship W4281755343A5037403084 @default.
• W4281755343 hasAuthorship W4281755343A5044450333 @default.
• W4281755343 hasAuthorship W4281755343A5045065281 @default.
• W4281755343 hasAuthorship W4281755343A5048411184 @default.
• W4281755343 hasAuthorship W4281755343A5077294466 @default.
• W4281755343 hasConcept C121608353 @default.
• W4281755343 hasConcept C126322002 @default.
• W4281755343 hasConcept C141071460 @default.
• W4281755343 hasConcept C143998085 @default.
• W4281755343 hasConcept C146357865 @default.
• W4281755343 hasConcept C151730666 @default.
• W4281755343 hasConcept C168563851 @default.
• W4281755343 hasConcept C203092338 @default.
• W4281755343 hasConcept C2776256026 @default.
• W4281755343 hasConcept C2777863537 @default.
• W4281755343 hasConcept C2777982462 @default.
• W4281755343 hasConcept C2908647359 @default.
• W4281755343 hasConcept C71924100 @default.
• W4281755343 hasConcept C86803240 @default.
• W4281755343 hasConcept C99454951 @default.
• W4281755343 hasConceptScore W4281755343C121608353 @default.
• W4281755343 hasConceptScore W4281755343C126322002 @default.
• W4281755343 hasConceptScore W4281755343C141071460 @default.
• W4281755343 hasConceptScore W4281755343C143998085 @default.
• W4281755343 hasConceptScore W4281755343C146357865 @default.
• W4281755343 hasConceptScore W4281755343C151730666 @default.
• W4281755343 hasConceptScore W4281755343C168563851 @default.
• W4281755343 hasConceptScore W4281755343C203092338 @default.
• W4281755343 hasConceptScore W4281755343C2776256026 @default.
• W4281755343 hasConceptScore W4281755343C2777863537 @default.
• W4281755343 hasConceptScore W4281755343C2777982462 @default.
• W4281755343 hasConceptScore W4281755343C2908647359 @default.
• W4281755343 hasConceptScore W4281755343C71924100 @default.
• W4281755343 hasConceptScore W4281755343C86803240 @default.
• W4281755343 hasConceptScore W4281755343C99454951 @default.
• W4281755343 hasFunder F4320328823 @default.
• W4281755343 hasIssue "16_suppl" @default.
• W4281755343 hasLocation W42817553431 @default.
• W4281755343 hasOpenAccess W4281755343 @default.
• W4281755343 hasPrimaryLocation W42817553431 @default.
• W4281755343 hasRelatedWork W1668400678 @default.
• W4281755343 hasRelatedWork W2051447115 @default.
• W4281755343 hasRelatedWork W2054423421 @default.
• W4281755343 hasRelatedWork W2349999257 @default.
• W4281755343 hasRelatedWork W2413232125 @default.
• W4281755343 hasRelatedWork W2414195948 @default.
• W4281755343 hasRelatedWork W2904759734 @default.
• W4281755343 hasRelatedWork W4280584969 @default.
• W4281755343 hasRelatedWork W4283212020 @default.
• W4281755343 hasRelatedWork W4306253774 @default.
• W4281755343 hasVolume "40" @default.
• W4281755343 isParatext "false" @default.
• W4281755343 isRetracted "false" @default.
• W4281755343 workType "article" @default.